Clinical Study of Neoadjuvant Chemoradiotherapy Combined with Immu-notherapy for Resectable Esophageal Squamous Cell Carcinoma
Objective To analyze the effect of neoadjuvant chemoradiotherapy combined with immunotherapy in pa-tients with resectable esophageal squamous cell carcinoma.Methods Twenty patients with operable thoracic esopha-geal squamous cell carcinoma admitted to Yangjiang People's Hospital from August 2022 to December 2023 were un-randomly selected as the study objects.All of them were treated with neoadjuvant chemoradiotherapy combined with immunotherapy,and the therapeutic efficacy and safety of the patients were analyzed.Results After neoadjuvant radio-therapy and chemotherapy,the preoperative efficacy was evaluated as complete remission in 2 cases(10.00%),partial remission in 17 cases(85.00%),stable disease in 1 case(5.00%),progressive disease in 0,and the objective remission rate was 95.00%.All patients underwent radical surgery successfully.The R0 resection rate was 100.00%.There were 9 cases of 0(45.00%),7 cases of 0～<11%(35.00%),2 cases of 11%～<51%(10.00%),and 2 cases of 51%～90%(10.00%)of residual tumor cells.The pathological complete response rate was 45.00%.After treatment,there were 2 patients with Ⅲ-Ⅳ granulocytopenia(10.00%),3 patients with severe digestive tract reaction(15.00%),0 with esophageal perforation and 4 patients with dermatitis(20.00%).Conclusion Neoadjuvant chemoradiotherapy com-bined with immunotherapy can reduce the tumor volume of patients,has a high pathological complete remission rate,can improve the success rate of radical surgery,and the adverse reaction is relatively mild,and has a good application effect in patients with resectable esophageal squamous cell carcinoma.
NETL
NSTL
万方数据
